Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma.
Cejalvo MJ, Bustamante G, González E, Vázquez-Álvarez J, García R, Ramírez-Payer Á, Pérez-Persona E, Abella E, Garzón S, García A, Jarque I, González MS, Sampol A, Motlló C, Martí JM, Alcalá M, Duro R, González Y, Sastre JL, Sarrà J, Lostaunau G, López R, de la Rubia J. Cejalvo MJ, et al. Among authors: motllo c. Ann Hematol. 2021 Jul;100(7):1769-1778. doi: 10.1007/s00277-021-04529-5. Epub 2021 Apr 22. Ann Hematol. 2021. PMID: 33885924
Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols.
Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Brunet S, Bergua J, Tormo M, García-Boyero R, Sarrà J, Del Potro E, Grande C, Barba P, Bernal T, Amigo ML, Grau J, Cervera J, Feliu E; PETHEMA Group, Spanish Society of Hematology. Motlló C, et al. Leuk Lymphoma. 2017 Jan;58(1):145-152. doi: 10.1080/10428194.2016.1177182. Epub 2016 Apr 27. Leuk Lymphoma. 2017. PMID: 27122129
Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia.
Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Mercadal S, González-Campos J, Moreno MJ, Barba P, Cervera M, Barrios M, Novo A, Bernal T, Hernández-Rivas JM, Abella E, Amigo ML, Tormo M, Martino R, Lavilla E, Bergua J, Serrano A, García-Belmonte D, Guàrdia R, Grau J, Feliu E; PETHEMA Group, Spanish Society of Hematology. Motlló C, et al. Leuk Lymphoma. 2018 Jan;59(1):146-154. doi: 10.1080/10428194.2017.1326596. Epub 2017 May 30. Leuk Lymphoma. 2018. PMID: 28554259
Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?
Gassiot S, González Y, Morgades M, Motlló C, Clapés V, Maluquer C, Ibarra G, Abril L, Ribera JM, Oriol A. Gassiot S, et al. Among authors: motllo c. Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):585-592.e1. doi: 10.1016/j.clml.2019.05.020. Epub 2019 Jun 5. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31255588
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.
Ocio EM, Motlló C, Rodríguez-Otero P, Martínez-López J, Cejalvo MJ, Martín-Sánchez J, Bladé J, García-Malo MD, Dourdil MV, García-Mateo A, de Arriba F, García-Sanz R, de la Rubia J, Oriol A, Lahuerta JJ, San-Miguel JF, Mateos MV. Ocio EM, et al. Among authors: motllo c. Br J Haematol. 2021 Feb;192(3):522-530. doi: 10.1111/bjh.16788. Epub 2020 Jun 5. Br J Haematol. 2021. PMID: 32501528 Free article. Clinical Trial.
Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myeloma.
Oriol A, Ibarra G, Abella E, Motlló C, Cibeira MT, Garcia A, Escoda L, Granell M, Ben-Azaiz R, Cervera M, Cabezudo E, Fernandez C, Rosiñol L. Oriol A, et al. Among authors: motllo c. Leuk Lymphoma. 2021 Jan;62(1):125-135. doi: 10.1080/10428194.2020.1817439. Epub 2020 Sep 15. Leuk Lymphoma. 2021. PMID: 32933355
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience.
Rodriguez-Otero P, Sirvent M, González-Rodríguez AP, Lavilla E, de Coca AG, Arguiñano JM, Martí JM, Cabañas V, Motlló C, de Cabo E, Encinas C, Murillo I, Hernández-Rivas JÁ, Pérez-Persona E, Casado F, Sampol A, García R, Blanchard MJ, Anguita M, Lafuente AP, Iñigo B, López A, Ribas P, Arnao M, Maldonado R, Bladé J, Mateos MV, Lahuerta JJ, San Miguel JF. Rodriguez-Otero P, et al. Among authors: motllo c. Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):413-420. doi: 10.1016/j.clml.2021.02.004. Epub 2021 Feb 16. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33741302
Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma.
Granell M, Senín A, Barata A, Cibeira MT, Gironella M, López-Pardo J, Motlló C, Garcia-Guiñón A, Ben-Azaiz R, Abella E, Soler A, Canet M, Martí JM, Martino R, Sierra J, de Larrea CF, Oriol A, Rosiñol L; Group for the Study of Myeloma and Amyloidosis of Catalonia (GEMMAC). Granell M, et al. Among authors: motllo c. Bone Marrow Transplant. 2021 Dec;56(12):2904-2910. doi: 10.1038/s41409-021-01429-0. Epub 2021 Aug 17. Bone Marrow Transplant. 2021. PMID: 34404917
Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas.
Moreno DF, Clapés V, Soler JA, González-Montes Y, Gironella M, Motlló C, Granell M, Abella E, García-Pintos M, García-Guiñón A, Cabezudo E, Bladé J, Rosiñol L. Moreno DF, et al. Among authors: motllo c. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):635-642. doi: 10.1016/j.clml.2022.04.014. Epub 2022 Apr 17. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35610120
27 results